These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 3113822

  • 1. Plasma levels of cortisol and corticosteroid binding globulin during use of Norplant-2 implants.
    Olsson SE, Odlind V, Hammond GL.
    Contraception; 1987 Apr; 35(4):353-61. PubMed ID: 3113822
    [Abstract] [Full Text] [Related]

  • 2. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL, Langley MS, Robinson PA, Nummi S, Lund L.
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [Abstract] [Full Text] [Related]

  • 3. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
    Olsson SE, Odlind V, Johansson ED, Nordström ML.
    Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
    [Abstract] [Full Text] [Related]

  • 4. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F.
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [Abstract] [Full Text] [Related]

  • 5. Influence of levonorgestrel contraceptive implants, NORPLANT, initiated early postpartum upon lactation and infant growth.
    Shaaban MM, Salem HT, Abdullah KA.
    Contraception; 1985 Dec; 32(6):623-35. PubMed ID: 3937665
    [Abstract] [Full Text] [Related]

  • 6. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmacological study.
    Olsson SE.
    Acta Obstet Gynecol Scand Suppl; 1987 Dec; 142():1-45. PubMed ID: 3116821
    [Abstract] [Full Text] [Related]

  • 7. Effect of Norplant implants on the pituitary-adrenal axis function and reserve capacity.
    Toppozada MK, Ramadan M, el-Sawi M, Mehanna MT, Khamis Y, Marzouk S.
    Contraception; 1997 Jan; 55(1):7-10. PubMed ID: 9013054
    [Abstract] [Full Text] [Related]

  • 8. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
    Elkik F, Basdevant A, Jackanicz TM, Guy-Grand B, Mercier-Bodard C, Conard J, Bardin CW, Corvol P.
    J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
    [Abstract] [Full Text] [Related]

  • 9. Androgen levels in women using Norplant implants.
    Olsson SE, Odlind V, Johansson E.
    Contraception; 1986 Aug; 34(2):157-67. PubMed ID: 2946553
    [Abstract] [Full Text] [Related]

  • 10. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
    Landgren BM, Johannisson E, Xing S, Aedo AR, Diczfalusy E.
    Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
    [Abstract] [Full Text] [Related]

  • 11. First year clinical experience with six levonorgestrel rods as subdermal contraception.
    Faundes A, Brache de Mejias V, Leon P, Robertson D, Alvarez F.
    Contraception; 1979 Aug; 20(2):167-75. PubMed ID: 487818
    [Abstract] [Full Text] [Related]

  • 12. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
    Mishell DR, Moore DE, Roy S, Brenner PF, Page MA.
    Am J Obstet Gynecol; 1978 Jan 01; 130(1):55-62. PubMed ID: 619648
    [Abstract] [Full Text] [Related]

  • 13. Adrenocortical function of patients using oral contraceptives.
    Kauppila A, Järvinen PA, Ylöstalo P, Reinilä M.
    Acta Obstet Gynecol Scand; 1974 Jan 01; 53(2):155-9. PubMed ID: 4362662
    [Abstract] [Full Text] [Related]

  • 14. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F, Brache V, Tejada AS, Faúndes A.
    Contraception; 1986 Feb 01; 33(2):111-9. PubMed ID: 3084166
    [Abstract] [Full Text] [Related]

  • 15. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
    Johannisson E, Brosens I, Cornillie F, Elder M, White J, Sheppard B, Hourihan H, d'Arcangues C, Belsey EM.
    Contraception; 1991 Apr 01; 43(4):361-74. PubMed ID: 1906792
    [Abstract] [Full Text] [Related]

  • 16. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
    Brache V, Alvarez-Sanchez F, Faundes A, Tejada AS, Cochon L.
    Contraception; 1990 Feb 01; 41(2):169-77. PubMed ID: 2107058
    [Abstract] [Full Text] [Related]

  • 17. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
    Joshi UM, Joshi JV, Donde UM, Sankoli GM, Virkar KD, Saxena BN.
    Contraception; 1985 Jan 01; 31(1):71-82. PubMed ID: 3921309
    [Abstract] [Full Text] [Related]

  • 18. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF, Mishell DR, Stanczyk FZ, Goebelsmann U.
    Am J Obstet Gynecol; 1977 Sep 15; 129(2):133-40. PubMed ID: 900174
    [Abstract] [Full Text] [Related]

  • 19. Interrelationship of serum levonorgestrel and sex hormone-binding globulin levels following vaginal and oral administration of combined steroid contraceptive tablets.
    Abdalla KA, Shabaan MM, Stanczyk FZ.
    Contraception; 1992 Feb 15; 45(2):111-8. PubMed ID: 1559334
    [Abstract] [Full Text] [Related]

  • 20. Metabolic changes during treatment with two different progestogens.
    Refn H, Kjaer A, Lebech AM, Borggaard B, Schierup L, Bremmelgaard A.
    Am J Obstet Gynecol; 1990 Jul 15; 163(1 Pt 2):374-7. PubMed ID: 2115298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.